Genenta Science (NASDAQ:GNTA) Stock Price Up 7% – Here’s Why

Genenta Science S.p.A. (NASDAQ:GNTA) was up 7% during mid-day trading on Tuesday . The company traded as high as $4.46 and last traded at $4.45. Approximately 2,004 shares traded hands during trading, a decline of 86% from the average daily volume of 14,696 shares. The stock had previously closed at $4.16.

Genenta Science Stock Performance

The stock’s 50 day moving average price is $3.90 and its 200-day moving average price is $4.35.

Institutional Investors Weigh In On Genenta Science

A number of hedge funds and other institutional investors have recently bought and sold shares of GNTA. Allianz SE raised its holdings in shares of Genenta Science by 126.2% in the first quarter. Allianz SE now owns 233,550 shares of the company’s stock worth $927,000 after buying an additional 130,300 shares during the last quarter. Algebris UK Ltd raised its holdings in shares of Genenta Science by 122.2% in the first quarter. Algebris UK Ltd now owns 100,000 shares of the company’s stock worth $368,000 after buying an additional 55,000 shares during the last quarter. Finally, Citadel Advisors LLC purchased a new position in shares of Genenta Science in the fourth quarter worth $46,000. Hedge funds and other institutional investors own 15.13% of the company’s stock.

About Genenta Science

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.